Uncategorized

Joseph Wright’s resignation is effective in January, and CEO and founder Fred Lampropoulos has been reappointed president.

Dexcom this week began rolling out the feature, which analyzes data to provide personalized tips and recommendations.

Lawmakers Tuesday night released the full text of a bipartisan agreement to fund the government through March. It could also reshape the pharmacy supply chain by reforming how controversial drug middlemen do business.

Industry experts said profit pressures and M&A contributed to job cuts. They said layoffs will likely continue into next year, but some expect the cuts to slow.

With about one month before inauguration day, check out a roundup of MedTech Dive’s coverage on what President-elect Donald Trump’s new administration means for medical device companies.

AbbVie’s blockbuster Humira held 105 patents, shielding the anti-inflammatory drug from biosimilar competition for more than 20 years. Proposed reforms could help prevent companies from extending exclusivity with such patent thickets.

The bankrupt health system had sought a buyer for the facility for months without success, according to court documents.

Suddenly the hottest thing in biopharma isn’t a new indication, disease target or modality—it’s manufacturing, and all of pharma is going to be vying for capacity and talent.

BioSpace Senior Editor Annalee Armstrong reflects on the year that was, and what’s to come in 2025.

Photys is eligible for up to $186 million from Novo Nordisk for its PHICS small molecules that pair a kinase to a disease-causing protein for phosphorylation.